Autonomic and Cardiovascular Probes
1 Beta-Blockers (Propranolol, Nebivolol)
Beta-blockers reduce sympathetic tone by blocking Ξ²-adrenergic receptors, lowering heart rate and blunting adrenergic drive. They probe whether sympathetic overactivity contributes to symptoms, and β at low doses β whether Ξ²2-adrenergic autoantibodies are involved.
1.1 If beta-blockers work
Improvement means excess adrenergic drive was driving symptoms; reducing it improved tolerance.
- Certainty
- Medium β rate/sympathetic effect is well established.
- Does NOT tell us
- whether the sympathetic overactivity is primary or compensatory.
- Action
- Supports sympatholytic strategies as a target.
- Level of action
- Symptom management.
If low-dose propranolol helps while other sympatholytic approaches do not, competitive antagonism of Ξ²2-adrenergic autoantibodies may be the mechanism β the drug occupies receptors that autoantibodies would otherwise dysregulate.
- Certainty
- Low for the autoantibody mechanism β research-stage; requires Ξ²2-AAb testing to confirm.
- Does NOT tell us
- whether the benefit is pharmacological rate control or autoantibody antagonism without antibody testing.
- Action
- Becomes relevant to test Ξ²2-adrenergic autoantibody status when low-dose response is disproportionate.
- Level of action
- Partial root cause (if autoantibody-mediated).
1.2 What a positive response does NOT reveal
- Whether sympathetic overactivity is primary or compensatory.
- Whether the benefit is pharmacological rate control or Ξ²2-autoantibody antagonism β these cannot be distinguished without autoantibody testing.
1.3 If beta-blockers do NOT work
- If fatigue worsens, reduced cardiac output has worsened the energy deficit β pointing to a low-SV subtype.
- Sympathetic overactivity may not be the dominant mechanism.
- The subtype may be venous- or volume-driven (low-SV POTS) rather than hyperadrenergic.
1.4 Key caveat
Beta-blockers that worsen fatigue indicate compensatory tachycardia β the worsening is itself diagnostic for low-SV POTS. Do not increase the dose; switch to ivabradine or volume strategies.
1.5 How beta-blockers combine with other medications
- Beta-blockers work + ivabradine works β converging evidence for a hyperadrenergic subtype.
- Beta-blockers WORSEN + ivabradine works β low-SV POTS; ivabradine slows the sinoatrial node without reducing contractility, whereas beta-blockade cut output.
- Beta-blockers work + fludrocortisone does not β pure hyperadrenergic POTS (not volume-depleted).
1.6 Compendium
The full pharmacodiagnostic entry β including mechanism-exclusion logic, dose-specific side-effect diagnostic patterns, combination diagnostics, and worsening risk profiles β is at Mechanistic Cascade Tracing: From Hypothesis to Clinical Probe (sec-12, Beta-Blockers entry).
2 Droxidopa
Norepinephrine prodrug that crosses the blood-brain barrier. It probes central norepinephrine deficiency β a documented CSF catecholamine reduction in ME/CFS (Walitt et al. 2024) β by supplying the precursor that the body converts into norepinephrine both peripherally and centrally.
2.1 If droxidopa works
Improvement means the reduced central catecholamine levels were contributing to symptoms β restoring norepinephrine improved function. This is one of few medications that directly probes the CSF catecholamine finding.
- Certainty
- Low to Medium β no ME/CFS RCT; mechanistic rationale is strong but unconfirmed in trials.
- Does NOT tell us
- why central norepinephrine is deficient.
- Action
- Supports central noradrenergic deficiency as a target; must be taken upright with blood pressure monitoring.
- Level of action
- Partial root cause.
2.2 What a positive response does NOT reveal
- Why central norepinephrine is deficient β candidates include inflammatory BH4 depletion via IDO, a metabolic constraint on catecholamine packaging, or HPA hypocortisolism reducing tyrosine hydroxylase activation.
- Whether the deficiency is primary or a downstream consequence.
2.3 If droxidopa does NOT work
- Central norepinephrine deficiency may not be functionally significant (it may be a downstream marker rather than a driver).
- Norepinephrine receptors may be downregulated by inflammation, so supplying more precursor does not restore signaling.
- Conversion of droxidopa to norepinephrine requires DOPA decarboxylase (B6/P5P-dependent) β if that cofactor is deficient, conversion is impaired.
- Dose may have been insufficient or duration too short.
2.4 Key caveat
Droxidopa raises blood pressure and is contraindicated if supine hypertension is already present; it must be taken upright only.
2.5 How droxidopa combines with other medications
- Droxidopa + low-dose aripiprazole (LDA) both work β combined noradrenergic and dopaminergic deficit.
- Droxidopa + LDN both work β inflammatory catecholamine depletion, consistent with the IDO/BH4 pathway.
- Droxidopa works + mitochondrial supplements do not β the norepinephrine deficit is not primarily from packaging failure.
2.6 Compendium
The full pharmacodiagnostic entry β including mechanism-exclusion logic, dose-specific side-effect diagnostic patterns, combination diagnostics, and worsening risk profiles β is at Mechanistic Cascade Tracing: From Hypothesis to Clinical Probe (sec-12, Droxidopa entry).
3 Fludrocortisone
Mineralocorticoid that expands plasma volume via sodium retention. It probes hypovolemia as an orthostatic mechanism: if low circulating volume is limiting venous return, expanding volume should improve tolerance.
3.1 If fludrocortisone works
Improvement means low plasma volume was contributing to orthostatic intolerance. Volume expansion restored adequate preload and cardiac filling.
- Certainty
- Medium for POTS β plasma volume expansion is a well-established effect.
- Does NOT tell us
- why plasma volume was low.
- Action
- Confirms volume expansion as a target; supports continued sodium/volume strategies with potassium monitoring.
- Level of action
- Partial root cause β corrects the volume deficit without addressing why volume regulation is impaired.
3.2 What a positive response does NOT reveal
- Why plasma volume is low β candidates include autoantibody-driven vascular dysregulation, HPA-axis hypocortisolism, or autonomically mediated sodium wasting.
- Whether the volume deficit is primary or secondary to another autonomic process.
3.3 If fludrocortisone does NOT work
- Ganglionic impairment is not volume-responsive (the pyridostigmine target).
- Venous pooling is not helped by extra volume alone (compression plus midodrine may be needed).
- In hyperadrenergic POTS, added volume can worsen hypertension rather than improve tolerance (ivabradine-responsive subtype).
- Dose may have been insufficient or duration too short.
3.4 Key caveat
Fludrocortisone risks hypokalemia, edema, and supine hypertension; potassium must be monitored. Non-response redirects toward ganglionic, venous, or hyperadrenergic mechanisms rather than a higher mineralocorticoid dose.
3.5 How fludrocortisone combines with other medications
- Fludrocortisone + pyridostigmine both work β combined hypovolemia and ganglionic impairment, the most common co-occurrence.
- Fludrocortisone works + ivabradine does not β hypovolemic, not hyperadrenergic, subtype.
- Fludrocortisone does not work + ivabradine works β pure hyperadrenergic POTS.
3.6 Compendium
The full pharmacodiagnostic entry β including mechanism-exclusion logic, dose-specific side-effect diagnostic patterns, combination diagnostics, and worsening risk profiles β is at Mechanistic Cascade Tracing: From Hypothesis to Clinical Probe (sec-12, Fludrocortisone entry).
4 Ivabradine
Selective If-channel blocker β reduces heart rate without affecting blood pressure, contractility, or autonomic tone. Because it slows the heart by acting directly on the sinoatrial node rather than by blunting sympathetic drive, it probes whether tachycardia is the primary problem (hyperadrenergic POTS) or a compensatory response to low stroke volume.
4.1 If ivabradine works
Heart-rate reduction improved tolerance, meaning the elevated heart rate was itself driving symptoms rather than compensating for a circulatory deficit. This points toward a hyperadrenergic POTS subtype.
- Certainty
- Medium β mechanism is well characterized; no ME/CFS-specific RCT.
- Does NOT tell us
- why sympathetic drive or sinoatrial automaticity is elevated (autoantibody, central noradrenergic dysregulation, deconditioning).
- Action
- Confirms tachycardia as a treatment target; supports continued rate control.
- Level of action
- Symptom management.
If symptoms worsen, the elevated heart rate was compensating for low stroke volume β reducing heart rate lowers cardiac output further. This is itself a diagnostic result: it distinguishes low-SV POTS from hyperadrenergic POTS.
- Certainty
- Medium β the worsening response is a direct physiological signal.
- Does NOT tell us
- the source of the low stroke volume (hypovolemia, venous pooling, reduced venous return).
- Action
- Redirect toward volume expansion and venoconstriction strategies rather than rate control.
- Level of action
- Symptom management (diagnostic redirection).
4.2 What a positive response does NOT reveal
- Whether the hyperadrenergic drive is primary or secondary to another process.
- The upstream cause of elevated sympathetic tone or sinoatrial automaticity.
4.3 If ivabradine does NOT work
- Tachycardia may not be the dominant mechanism β venous pooling or hypovolemia may predominate.
- Dose may have been insufficient or duration too short.
- Symptoms may arise from a non-cardiovascular source (central fatigue, PEM).
4.4 Key caveat
Ivabradine in low-SV POTS can worsen symptoms β reducing heart rate in a patient whose tachycardia compensates for low stroke volume lowers cardiac output further. Worsening on ivabradine should prompt reassessment for a low-SV subtype rather than a dose increase.
4.5 How ivabradine combines with other medications
- Ivabradine works + pyridostigmine does not β hyperadrenergic POTS; a ganglionic transmission deficit is not the dominant mechanism.
- Ivabradine works + fludrocortisone does not β hyperadrenergic, not hypovolemic, POTS.
- Ivabradine WORSENS + midodrine works β low-SV POTS with venous pooling; reducing heart rate lowers output further while venoconstriction restores return.
4.6 Compendium
The full pharmacodiagnostic entry β including mechanism-exclusion logic, dose-specific side-effect diagnostic patterns, combination diagnostics, and worsening risk profiles β is at Mechanistic Cascade Tracing: From Hypothesis to Clinical Probe (sec-12, Ivabradine entry).
5 Midodrine
Ξ±1-adrenergic agonist that constricts peripheral veins and arterioles. It probes whether venous pooling or inadequate vasoconstriction is the orthostatic mechanism, because it raises peripheral vascular tone without expanding volume or altering central drive.
5.1 If midodrine works
Improvement means blood was pooling in the periphery or vascular tone was inadequate to maintain venous return. This is more likely with connective tissue laxity or autonomic neuropathy, where vessels fail to constrict appropriately on standing.
- Certainty
- Medium β mechanism well characterized; combination data available (Pavic et al. 2025).
- Does NOT tell us
- whether the vasoconstriction failure is structural (connective tissue laxity) or neurogenic (autonomic neuropathy).
- Action
- Supports venoconstriction as a treatment target; combining with pyridostigmine is superior to monotherapy (Pavic et al. 2025).
- Level of action
- Symptom management.
5.2 What a positive response does NOT reveal
- Whether inadequate vasoconstriction is the root cause or downstream of autonomic denervation.
- The specific cause of vascular laxity or autonomic dysfunction.
5.3 If midodrine does NOT work
- Venous pooling may not be dominant; the mechanism may be hypovolemia (fludrocortisone-responsive).
- In hyperadrenergic POTS, excessive sympathetic tone is already present β adding an Ξ±1 agonist raises blood pressure without improving orthostatic tolerance.
- Does not address ganglionic transmission impairment (the pyridostigmine target).
- Dose may have been insufficient or duration too short.
5.4 Key caveat
Midodrine raises blood pressure and can cause supine hypertension; it should be dosed while upright and avoided near bedtime. A lack of benefit points toward a non-venous mechanism rather than a need for higher doses.
5.5 How midodrine combines with other medications
- Midodrine + pyridostigmine both work β dual mechanism of vasoconstriction plus ganglionic transmission; meta-analysis confirms this combination is superior to monotherapy (Pavic et al. 2025).
- Midodrine works + fludrocortisone does not β venous pooling that is not volume-responsive.
- Midodrine does not work + fludrocortisone works β hypovolemia, not venous tone, is the mechanism.
5.6 Compendium
The full pharmacodiagnostic entry β including mechanism-exclusion logic, dose-specific side-effect diagnostic patterns, combination diagnostics, and worsening risk profiles β is at Mechanistic Cascade Tracing: From Hypothesis to Clinical Probe (sec-12, Midodrine entry).